IDEAS home Printed from https://ideas.repec.org/f/pgr657.html
   My authors  Follow this author

Paul Greenberg

Personal Details

First Name:Paul
Middle Name:
Last Name:Greenberg
Suffix:
RePEc Short-ID:pgr657

Research output

as
Jump to: Articles

Articles

  1. Dominic Pilon & Holly Szukis & Kruti Joshi & David Singer & John J. Sheehan & Jennifer W. Wu & Patrick Lefebvre & Paul Greenberg, 2020. "US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study," PharmacoEconomics - Open, Springer, vol. 4(1), pages 119-131, March.
  2. David Thesmar & David Sraer & Lisa Pinheiro & Nick Dadson & Razvan Veliche & Paul Greenberg, 2019. "Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges," PharmacoEconomics, Springer, vol. 37(6), pages 745-752, June.
  3. Dominic Pilon & Kruti Joshi & John J Sheehan & Miriam L Zichlin & Peter Zuckerman & Patrick Lefebvre & Paul E Greenberg, 2019. "Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-16, October.
  4. Paul Greenberg, 2014. "Cost of Illness: An Ongoing Battle Worth Fighting," PharmacoEconomics, Springer, vol. 32(12), pages 1151-1152, December.
  5. Atanu Saha & Henry Grabowski & Howard Birnbaum & Paul Greenberg & Oded Bizan, 2006. "Generic Competition in the US Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 13(1), pages 15-38.
  6. Berndt, Ernst R. & Finkelstein, Stan N. & Greenberg, Paul E. & Howland, Robert H. & Keith, Alison & Rush, A. John & Russell, James & Keller, Martin B., 1998. "Workplace performance effects from chronic depression and its treatment," Journal of Health Economics, Elsevier, vol. 17(5), pages 511-535, October.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

  1. David Thesmar & David Sraer & Lisa Pinheiro & Nick Dadson & Razvan Veliche & Paul Greenberg, 2019. "Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges," PharmacoEconomics, Springer, vol. 37(6), pages 745-752, June.

    Cited by:

    1. Mathias Bärtl & Simone Krummaker, 2020. "Prediction of Claims in Export Credit Finance: A Comparison of Four Machine Learning Techniques," Risks, MDPI, vol. 8(1), pages 1-27, March.
    2. Fatma Khamis Al Badi & Khawla Ali Alhosani & Fauzia Jabeen & Agata Stachowicz-Stanusch & Nazia Shehzad & Wolfgang AMANN, 2022. "Challenges of AI Adoption in the UAE Healthcare," Vision, , vol. 26(2), pages 193-207, June.
    3. Araz Zirar, 2023. "Can artificial intelligence’s limitations drive innovative work behaviour?," Review of Managerial Science, Springer, vol. 17(6), pages 2005-2034, August.
    4. Cedric Kuang, 2019. "Insight of Artificial Intelligence Application in Healthcare," International Journal of Sciences, Office ijSciences, vol. 8(08), pages 50-55, August.
    5. Zirar, Araz & Ali, Syed Imran & Islam, Nazrul, 2023. "Worker and workplace Artificial Intelligence (AI) coexistence: Emerging themes and research agenda," Technovation, Elsevier, vol. 124(C).
    6. Zahlan, Ahmed & Ranjan, Ravi Prakash & Hayes, David, 2023. "Artificial intelligence innovation in healthcare: Literature review, exploratory analysis, and future research," Technology in Society, Elsevier, vol. 74(C).

  2. Atanu Saha & Henry Grabowski & Howard Birnbaum & Paul Greenberg & Oded Bizan, 2006. "Generic Competition in the US Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 13(1), pages 15-38.

    Cited by:

    1. Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity," NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 243-271, National Bureau of Economic Research, Inc.
    2. Russian Presidential Academy of National Economy and Public Administration authors collective, 2012. "The Consequences of Weak Competition: Quantitative Evaluation and Policy Implications (Think Tank Report)," Ekonomicheskaya Politika / Economic Policy, Russian Presidential Academy of National Economy and Public Administration, vol. 6, pages 1-49.
    3. Ernst R. Berndt & Thomas G. McGuire & Joseph P. Newhouse, 2011. "A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets," NBER Working Papers 16879, National Bureau of Economic Research, Inc.
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
    6. Newham, M. & Seldeslachts, J. & Banal-Estanol, A., 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 18/03, Department of Economics, City University London.
    7. Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
    8. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    9. Liu, Ya-Ming & Yang, Yea-Huei Kao & Hsieh, Chee-Ruey, 2012. "Regulation and competition in the Taiwanese pharmaceutical market under national health insurance," Journal of Health Economics, Elsevier, vol. 31(3), pages 471-483.
    10. Christina Kelton & Lenisa Chang & Jeff Guo & Yan Yu & Edmund Berry & Boyang Bian & Pamela Heaton, 2014. "Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 165-177, April.
    11. Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
    12. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
    13. Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Discussion Paper Series in Economics 20/2018, Norwegian School of Economics, Department of Economics.
    14. Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
    15. Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
    16. Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
    17. Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-Chong, 2022. "Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis," MPRA Paper 113923, University Library of Munich, Germany.
    18. Iván Moreno-Torres & Jaume Puig-Junoy & Joan-Ramon Borrell, 2009. "Generic Entry into the Regulated Spanish Pharmaceutical Market," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 34(4), pages 373-388, June.
    19. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.
    20. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016. "Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry," RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
    21. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    22. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
    23. Liu, Ya-Ming & Cheng, Jur-Shan, 2012. "Determinants of generic entry in the regulated Taiwanese prescription drug market," Health Policy, Elsevier, vol. 108(2), pages 228-235.
    24. Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
    25. Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
    26. Granlund, David & Bergman, Mats A., 2018. "Price competition in pharmaceuticals – Evidence from 1303 Swedish markets," Journal of Health Economics, Elsevier, vol. 61(C), pages 1-12.
    27. Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
    28. Shastitko, Andrey E. (Шаститко, Андрей) & Golovanova, Svetlana (Голованова, Светлана) & Kurdin, Alexander (Курдин, Александр) & Novikov, Vadim (Новиков, Вадим) & Pavlova, Natalia (Павлова, Наталья), 2014. "Macroeconomic Effects of Competition Restrictions [Макроэкономические Эффекты Ограничений Конкуренции]," Published Papers om18, Russian Presidential Academy of National Economy and Public Administration.
    29. Phill O’Neill & Jorge Mestre-Ferrandiz & Ruth Puig-Peiro & Jon Sussex, 2013. "Projecting Expenditure on Medicines in the UK NHS," PharmacoEconomics, Springer, vol. 31(10), pages 933-957, October.
    30. Gerard T. Vondeling & Qi Cao & Maarten J. Postma & Mark H. Rozenbaum, 2018. "The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 653-660, October.
    31. Claudio Lucarelli & Sean Nicholson & Minjae Song, 2010. "Bundling Among Rivals: A Case of Pharmaceutical Cocktails," NBER Working Papers 16321, National Bureau of Economic Research, Inc.
    32. Yi-Wen Tsai & Yu-Wen Wen & Weng-Foung Huang & Ken Kuo & Pei-Fen Chen & Hsin-Wei Shih & Yue-Chune Lee, 2010. "Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 279-290, June.
    33. Henry G. Grabowski & David B. Ridley & Kevin A. Schulman, 2007. "Entry and competition in generic biologics," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 439-451.
    34. Costa-Font, Joan & McGuire, Alistair & Varol, Nebibe, 2014. "Price regulation and relative delays in generic drug adoption," Journal of Health Economics, Elsevier, vol. 38(C), pages 1-9.
    35. Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 357, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.

  3. Berndt, Ernst R. & Finkelstein, Stan N. & Greenberg, Paul E. & Howland, Robert H. & Keith, Alison & Rush, A. John & Russell, James & Keller, Martin B., 1998. "Workplace performance effects from chronic depression and its treatment," Journal of Health Economics, Elsevier, vol. 17(5), pages 511-535, October.

    Cited by:

    1. Ernst R.Berndt, 2000. "On the economic impacts of medical treatments: work productivity and functioning," Estudios de Economia, University of Chile, Department of Economics, vol. 27(2 Year 20), pages 181-198, December.
    2. Angelucci, Manuela & Bennett, Daniel M, 2021. "The Economic Impact of Depression Treatment in India," IZA Discussion Papers 14393, Institute of Labor Economics (IZA).
    3. Meltem Daysal, N. & Orsini, C., 2012. "The Miracle Drug : Hormone Replacement Therapy and Labor Market Behavior of Middle-Aged Women," Other publications TiSEM ce29046c-47bf-4f33-87af-3, Tilburg University, School of Economics and Management.
    4. Souvik Banerjee & Pinka Chatterji & Kajal Lahiri, 2017. "Effects of Psychiatric Disorders on Labor Market Outcomes: A Latent Variable Approach Using Multiple Clinical Indicators," Health Economics, John Wiley & Sons, Ltd., vol. 26(2), pages 184-205, February.
    5. Yuan-Pang Wang & Clarice Gorenstein, 2014. "Attitude and Impact of Perceived Depression in the Workplace," IJERPH, MDPI, vol. 11(6), pages 1-16, June.
    6. Björn Nilsson, 2017. "Parental depressive symptoms and the child labor-schooling nexus: evidence from Mexico," Working Papers DT/2017/06, DIAL (Développement, Institutions et Mondialisation).
    7. Lars J. Lefgren & Olga B. Stoddard & John E. Stovall, 2018. "Are Two Bads Better Than One? A Model of Sensory Limitations," NBER Working Papers 25060, National Bureau of Economic Research, Inc.
    8. Pinka Chatterji & Margarita Alegria & Mingshan Lu & David Takeuchi, 2005. "Psychiatric Disorders and Labor Market Outcomes: Evidence from the National Latino and Asian American Study," NBER Working Papers 11893, National Bureau of Economic Research, Inc.
    9. Maclean, Johanna Catherine, 2013. "The health effects of leaving school in a bad economy," Journal of Health Economics, Elsevier, vol. 32(5), pages 951-964.
    10. Mark G. Duggan, 2003. "Does Medicaid Pay Too Much for Prescription Drugs? A Case Study of Atypical Anti-Psychotics," NBER Working Papers 9626, National Bureau of Economic Research, Inc.
    11. Baranov, Victoria & Bennett, Daniel & Kohler, Hans-Peter, 2015. "The indirect impact of antiretroviral therapy: Mortality risk, mental health, and HIV-negative labor supply," Journal of Health Economics, Elsevier, vol. 44(C), pages 195-211.
    12. Noonan, Kelly & Corman, Hope & Reichman, Nancy E., 2016. "Effects of maternal depression on family food insecurity," Economics & Human Biology, Elsevier, vol. 22(C), pages 201-215.
    13. Pinka Chatterji & Margarita Alegria & David Takeuchi, 2008. "Psychiatric Disorders and Labor Market Outcomes: Evidence from the National Comorbidity Survey - Replication," NBER Working Papers 14404, National Bureau of Economic Research, Inc.
    14. Craig L. Garthwaite, 2012. "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors," American Economic Journal: Applied Economics, American Economic Association, vol. 4(3), pages 116-137, July.
    15. Drusilla K. Brown & Thomas Downes & Karen Eggleston & Ratna Kumari, 2006. "Human Resource Management Technology Diffusion Through Global Supply Chains: Productivity and Workplace Based Health Care," Discussion Papers Series, Department of Economics, Tufts University 0616, Department of Economics, Tufts University.
    16. Nafilyan, Vahé & Pabon, Mauricio Avendano & de Coulon, Augustin, 2021. "The Causal Impact of Depression on Cognitive Functioning: Evidence from Europe," IZA Discussion Papers 14049, Institute of Labor Economics (IZA).
    17. Julie Donohue & Harold Pincus, 2007. "Reducing the Societal Burden of Depression," PharmacoEconomics, Springer, vol. 25(1), pages 7-24, January.
    18. Solomon, Keisha T. & Dasgupta, Kabir, 2022. "State mental health insurance parity laws and college educational outcomes," Journal of Health Economics, Elsevier, vol. 86(C).
    19. Steinhauer, Andreas & Bíró, Anikó & Dieterle, Steven, 2019. "Motherhood Timing and the Child Penalty: Bounding the Returns to Delay," CEPR Discussion Papers 13732, C.E.P.R. Discussion Papers.
    20. Frederick J. Zimmerman & Wayne Katon, 2005. "Socioeconomic status, depression disparities, and financial strain: what lies behind the income‐depression relationship?," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1197-1215, December.
    21. Joan Costa-Font & Joan Gil, 2008. "Would Socio-Economic Inequalities in Depression Fade Away with Income Transfers?," Journal of Happiness Studies, Springer, vol. 9(4), pages 539-558, December.
    22. Office of Health Economics, 2003. "Mental Health Economics and Policy in a Global Context," Seminar Briefing 000482, Office of Health Economics.
    23. Susan L. Ettner & Johanna Catherine Maclean & Michael T. French, 2011. "Does Having a Dysfunctional Personality Hurt Your Career? Axis II Personality Disorders and Labor Market Outcomes," Industrial Relations: A Journal of Economy and Society, Wiley Blackwell, vol. 50(1), pages 149-173, January.
    24. Pinka Chatterji & Margarita Alegria & David Takeuchi, 2009. "Racial/Ethnic Differences in the Effects of Psychiatric Disorders on Employment," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 37(3), pages 243-257, September.
    25. Stefanie Schurer & Michael Alspach & Jayden MacRae & Gregory Martin, 2016. "The Medical Care Costs of Mood Disorders: A Coarsened Exact Matching Approach," The Economic Record, The Economic Society of Australia, vol. 92(296), pages 81-93, March.
    26. Jason Fletcher, 2013. "Adolescent Depression and Adult Labor Market Outcomes," Southern Economic Journal, John Wiley & Sons, vol. 80(1), pages 26-49, July.
    27. Craig Garthwaite & John A. Graves & Tal Gross & Zeynal Karaca & Victoria R. Marone & Matthew J. Notowidigdo, 2019. "All Medicaid Expansions Are Not Created Equal: The Geography and Targeting of the Affordable Care Act," NBER Working Papers 26289, National Bureau of Economic Research, Inc.
    28. Matthew Lang, 2013. "The Impact Of Mental Health Insurance Laws On State Suicide Rates," Health Economics, John Wiley & Sons, Ltd., vol. 22(1), pages 73-88, January.
    29. Attila Cseh, 2008. "The Effects of Depressive Symptoms on Earnings," Southern Economic Journal, John Wiley & Sons, vol. 75(2), pages 383-409, August.
    30. Mark Attridge & Steven P. Dickens, 2022. "Health and Work Outcomes of Brief Counseling From an EAP in Vermont: Follow-Up Survey Results, Client Satisfaction, and Estimated Cost Savings," SAGE Open, , vol. 12(1), pages 21582440221, March.
    31. Andersen, Martin, 2015. "Heterogeneity and the effect of mental health parity mandates on the labor market," Journal of Health Economics, Elsevier, vol. 43(C), pages 74-84.
    32. Jason M. Fletcher, 2008. "Adolescent depression: diagnosis, treatment, and educational attainment," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1215-1235, November.
    33. Ernst R. Berndt & Anupa Bir & Susan H. Busch & Richard G. Frank & Sharon-Lise T. Normand, 2000. "The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected Outcome Variations, and Price Indexes," NBER Working Papers 7816, National Bureau of Economic Research, Inc.
    34. Kelly Noonan & Hope Corman & Nancy E. Reichman, 2014. "Effects of Maternal Depression on Family Food Insecurity," NBER Working Papers 20113, National Bureau of Economic Research, Inc.
    35. Tefft, Nathan, 2012. "Mental health and employment: The SAD story," Economics & Human Biology, Elsevier, vol. 10(3), pages 242-255.
    36. Stephen Almond & Andrew Healey, 2003. "Mental Health and Absence from Work: New Evidence from the UK Quarterly Labour Force Survey," Work, Employment & Society, British Sociological Association, vol. 17(4), pages 731-742, December.
    37. Follmer, Kayla B. & Follmer, D. Jake, 2021. "Longitudinal relations between workplace mistreatment and engagement – The role of suicidal ideation among employees with mood disorders," Organizational Behavior and Human Decision Processes, Elsevier, vol. 162(C), pages 206-217.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Paul Greenberg should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.